JP Morgan Chase
GLMD icon

JP Morgan Chase’s Galmed Pharmaceuticals GLMD Stock Holding History

JP Morgan Chase’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4
Closed -$1K – 6624
2022
Q1 		$1K Buy
+4
New +$1.13K ﹤0.01% 6476
2020
Q2 		– Sell
-13
Closed -$8K – 5502
2020
Q1 		$8K Sell
13
-282
-96% -$268K ﹤0.01% 5073
2019
Q4 		$307K Sell
295
-47
-14% -$40.4K ﹤0.01% 4499
2019
Q3 		$294K Buy
342
+179
+110% +$180K ﹤0.01% 4442
2019
Q2 		$183K Sell
163
-42
-20% -$54.2K ﹤0.01% 4697
2019
Q1 		$302K Buy
205
+193
+1,608% +$281K ﹤0.01% 4447
2018
Q4 		$14K Buy
+12
New +$21K ﹤0.01% 5382
2018
Q2 		– Sell
-21
Closed -$21K – 5582
2018
Q1 		$21K Sell
21
-1
-5% -$1.46K ﹤0.01% 5072
2017
Q4 		$36K Buy
22
+19
+633% +$28.1K ﹤0.01% 4997
2017
Q3 		$5K Buy
+3
New +$4.15K ﹤0.01% 4796

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's GLMD Position: Q2 2022 in Review

JP Morgan Chase sold out of Galmed Pharmaceuticals (GLMD) in Q2 2022, closing a stake of 4 shares — an estimated $1K sold.

JP Morgan Chase first reported a position in GLMD in Q3 2017 and held it in 10 quarters. The position peaked at $307K in Q4 2019. 22 funds tracked by Wall St. Rank hold GLMD as of Q2 2022.

  • JP Morgan Chase reported no remaining Galmed Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • JP Morgan Chase sold 4 Galmed Pharmaceuticals shares in Q2 2022, an estimated $1K.
  • JP Morgan Chase first reported a position in Galmed Pharmaceuticals in Q3 2017 and held it in 10 quarters.
  • JP Morgan Chase's Galmed Pharmaceuticals position peaked at $307K in Q4 2019.
  • 22 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2022.

Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.